Crescent Biopharma, Inc. (CBIO NASDAQ) stock market data APIs
$11.7663
0.89(7.6%)
as of October 16, 2026
Try our APIs with
free plan!
Crescent Biopharma, Inc. Financial Data Overview
Price chart is built with
Anychart
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Prev. Close
11.7663
Open
12.6529
High
12.6998
Low
11.7579
52 wk Range
8.72-27.41
Market Cap
440 M
Shares Outstanding
37 144 K
Revenue
11 883 K
EPS
-0.74
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Crescent Biopharma, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Crescent Biopharma, Inc. data using free add-ons & libraries
Get Crescent Biopharma, Inc. Fundamental Data
Crescent Biopharma, Inc. Fundamental data includes:
- Net Revenue: 11 883 K
- EBITDA: -170 028 000
- Earnings Per Share: -7
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Crescent Biopharma, Inc. Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-07-30
- EPS/Forecast: -0.78
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Crescent Biopharma, Inc. News
New
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Crescent Biopharma, Inc. More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial monotherapy data from ASCEND in ...
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda. Continue Reading
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-0...
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma, Inc. Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previou...
Get Crescent Biopharma, Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.